Search

Royalty Pharma PLC (Class A)

Deschisă

SectorSănătate

58.1 -0.27

Rezumat

Modificarea prețului

24h

Curent

Minim

57.65

Maxim

58.48

Indicatori cheie

By Trading Economics

Venit

-589M

-295M

Vânzări

44M

674M

P/E

Medie Sector

31.419

55.725

EPS

1.32

Randament dividend

1.56

Marjă de profit

-43.713

Angajați

100

EBITDA

-387M

176M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+12.74% upside

Dividende

By Acuity

Randament dividend

Medie Sector

1.56%

2.25%

Următoarele câștiguri

4 nov. 2026

Data viitoare de dividende

9 dec. 2026

Următoarea dată ex-dividende

13 nov. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

848M

34B

Deschiderea anterioară

58.37

Închiderea anterioară

58.1

Sentimentul știrilor

By Acuity

15%

85%

11 / 339 Clasament în Healthcare

Royalty Pharma PLC (Class A) Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

24 sept. 2026, 19:25 UTC

Royalty Pharma PLC shares are rising, reflecting notable market strength, although they remain below the 20-day moving average and near the one-month range's lower end.

23 sept. 2026, 19:51 UTC

Royalty Pharma PLC shares fell sharply, reaching a session low just before 1 PM, as the broader market declines and remains below its 20-day moving average.

22 sept. 2026, 20:06 UTC

Correlated Moves

Royalty Pharma PLC is trading higher, likely influenced by Amgen Inc.'s positive Phase 3 OASIZ 301 study results, despite earlier pulling back from a session high.

21 sept. 2026, 20:06 UTC

Royalty Pharma PLC's shares are trading roughly flat, remaining below the 20-day moving average and near the lower end of their one-month range.

18 sept. 2026, 20:06 UTC

Royalty Pharma PLC shares fell sharply on Friday, closing significantly below its 20-day moving average and near the lower end of its one-month range.

17 sept. 2026, 23:06 UTC

Royalty Pharma PLC declined in after-market trading, moving lower since Thursday's close and positioning it below its 20-day moving average.

16 sept. 2026, 23:06 UTC

Royalty Pharma PLC is trading lower in after-market hours, remaining significantly below its 20-day moving average and near the lower end of its one-month range.

15 sept. 2026, 23:16 UTC

News

Royalty Pharma announced a $7.5 million donation to Blood Cancer United. Shares are lower in after-market trading amid rising Treasury yields.

14 sept. 2026, 20:07 UTC

Royalty Pharma PLC shares are higher today, reflecting a modest gain since Friday. Broader market concerns over rising crude oil prices may be influencing sentiment.

11 sept. 2026, 20:08 UTC

Royalty Pharma PLC shares are lower today, pulling back from earlier gains amid broader market dynamics and inflation pressures influencing Federal Reserve policy.

10 sept. 2026, 23:46 UTC

Royalty Pharma PLC shares are higher in after-market trading, continuing a rise since Thursday's close, though still below the 20-day moving average.

9 sept. 2026, 20:07 UTC

News

Royalty Pharma shares lower today, following a decline after Novartis' trial failure. Analysts suggest the drop may be overdone amid stable royalty expectations.

8 sept. 2026, 21:01 UTC

Royalty Pharma PLC shares are higher in after-market hours, reflecting broader market dynamics despite no specific company news identified.

5 sept. 2026, 00:01 UTC

News

Royalty Pharma PLC shares fell in after-market hours following the failed Phase 3 trial of pelacarsen, impacting its funding agreement with Ionis.

4 sept. 2026, 22:14 UTC

Royalty Pharma PLC shares are trading lower during after-market hours, breaking a trend of higher daily closes. No specific news was identified for the decline.

3 sept. 2026, 23:05 UTC

Royalty Pharma PLC shares are lower in after-market hours, with no specific news identified for the decline. The stock remains above its 20-day moving average.

2 sept. 2026, 23:06 UTC

Royalty Pharma PLC shares are lower in after-market hours, reflecting a slight decline since Wednesday's close, despite earlier recovery attempts.

1 sept. 2026, 20:09 UTC

Royalty Pharma PLC is rising as strength in the pharmaceuticals sub-sector boosts shares. The stock remains near its one-month high despite a recent pullback.

31 aug. 2026, 23:16 UTC

Royalty Pharma PLC shares are higher in after-market trading, reflecting positive market sentiment. The stock remains near the upper end of its one-month trading range.

28 aug. 2026, 20:07 UTC

Royalty Pharma PLC shares are lower today amid broader market declines and rising U.S. Treasury yields, reflecting ongoing volatility in the pharmaceuticals sector.

27 aug. 2026, 23:11 UTC

Royalty Pharma PLC shares are higher in after-market trading, supported by a favorable performance backdrop and positioning above the 20-day moving average.

26 aug. 2026, 23:16 UTC

Royalty Pharma PLC shares are higher in after-market trading, currently above their 20-day moving average and near the upper end of their one-month range.

25 aug. 2026, 20:07 UTC

Royalty Pharma PLC shares are higher today, continuing an upward trend since Monday. Lower Treasury yields are supporting investor sentiment in the market.

24 aug. 2026, 20:06 UTC

Royalty Pharma PLC shares are near unchanged as market sentiment is influenced by rising oil prices and geopolitical tensions from new U.S. sanctions against Iran.

21 aug. 2026, 19:26 UTC

Royalty Pharma PLC shares are higher, reflecting a broader rebound in U.S. stocks amid economic uncertainties and rising inflation. The asset remains above its 20-day moving average.

20 aug. 2026, 23:11 UTC

Royalty Pharma PLC shares are lower in after-market hours, continuing a decline from earlier in the session amid mixed broader market sentiment.

19 aug. 2026, 20:02 UTC

Royalty Pharma PLC shares are higher today, driven by strong investor interest in pharmaceuticals and unusually high market volume during regular trading hours.

18 aug. 2026, 23:21 UTC

Royalty Pharma PLC shares are higher in after-market trading, continuing an upward trend from previous sessions. No specific news was identified for this movement.

17 aug. 2026, 19:36 UTC

Royalty Pharma PLC shares are trading higher during Monday's session, recovering from an earlier dip and remaining above the 20-day moving average.

15 aug. 2026, 00:01 UTC

Royalty Pharma PLC shares are lower in after-market hours, continuing a routine decline since Friday's close amid mixed global equity market performance.

Comparație

Modificare preț

Royalty Pharma PLC (Class A) Așteptări

Obiectiv de preț

By TipRanks

12.74% sus

Prognoză pe 12 luni

Medie 65.714 USD  12.74%

Maxim 70 USD

Minim 62 USD

În baza a 7 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruRoyalty Pharma PLC (Class A) - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

7 ratings

7

Cumpărare

0

Păstrare

0

Vânzare

Sentiment

By Acuity

11 / 339 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Royalty Pharma PLC (Class A)

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.